3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
2
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
129
Carcinoma, Non-Small-Cell Lung
101
Prostatic Neoplasms
62
Colorectal Neoplasms
48
Nasopharyngeal Carcinoma
45
Neoplasms
44
Multiple Myeloma
41
Stomach Neoplasms
35
Leukemia, Myeloid, Acute
32
Ovarian Neoplasms
31
Neoplasm Metastasis
31
Lung Neoplasms
31
Carcinoma, Hepatocellular
29
Squamous Cell Carcinoma of Head and Neck
27
Rectal Neoplasms
27
Pancreatic Neoplasms
26
Triple Negative Breast Neoplasms
25
Recurrence
25
Small Cell Lung Carcinoma
21
Brain Neoplasms
21
Esophageal Neoplasms
20
Colonic Neoplasms
20
Uterine Cervical Neoplasms
19
Lymphoma, Large B-Cell, Diffuse
17
Head and Neck Neoplasms
17
Urinary Bladder Neoplasms
16
Leukemia, Lymphocytic, Chronic, B-Cell
16
Esophageal Squamous Cell Carcinoma
16
Carcinoma, Renal Cell
16
Myasthenia Gravis
15
Interventions
palbociclib
1
lenvatinib
1
cabozantinib
1
belzutifan
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recruiting
×
von Hippel-Lindau Disease
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled